Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology

NCT07276152 | Recruiting

• 1 other identifier: 2025-01817, kt25christcrain6
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting

Conditions

Sonic Augmentation Technology

Keywords

Arginine Vasopressin Deficiency; oxytocin; diabetes insipidus

Outcome Measures

Primary Outcomes (2)

• Change in oxytocin levels in healthy adults after listening to SAT enhanced music vs. placebo music

  Oxytocin release in response to music enhanced with SAT in healthy participants compared to oxytocin release in response to placebo stimulation in healthy participants

  up to 30 min

• Change in oxytocin levels in patients with AVP-deficiency after listening to SAT enhanced music

  baseline is defined as 100% of the initial value, in patients with AVP-Deficiency. Any changes will be expressed as a percentage relative to this baseline. Maximum oxytocin level observed between baseline and 30 minutes will be determined.

  up to 30 minutes

Secondary Outcomes (16)

• Area under the concentration time curve in plasma oxytocin

  up to 30 minutes

• Peak change in plasma oxytocin

  up to 30 minutes

• Time course of plasma oxytocin levels

  up to 30 minutes

• Time course of plasma copeptin

  up to 30 minutes

• Time course of plasma cortisol

  up to 30 minutes

Study Arms (3)

Sonic augmentation technology (SAT) - placebo music

EXPERIMENTAL

Participants will listen to music enhanced with SAT in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to placebo music

Other: sonic augmentation technology

placebo music- sonic augmentation technology (SAT) music

EXPERIMENTAL

Participants will listen to placebo in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to music enhanced with SAT

Other: sonic augmentation technology

Sonic augmentation technology (SAT) in patients

EXPERIMENTAL

Patients have one study visit listening to SAT

Other: sonic augmentation technology

Interventions

sonic augmentation technology OTHER

Participants/ patients listen to music enhanced with sonic aumentation technology

Sonic augmentation technology (SAT) - placebo music; Sonic augmentation technology (SAT) in patients; placebo music- sonic augmentation technology (SAT) music

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult healthy controls
• No medication, except hormonal contraception

You may not qualify if:

• Participation in a trial with investigational drugs within 30 days
• Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
• Consumption of alcoholic beverages \>15 drinks/week
• Tobacco smoking \>10 cigarettes/day
• Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
• Psychotic disorder in first-degree relatives
• Pregnancy and breastfeeding
• Part 2:
• Confirmed diagnosis of AVP-Deficiency
• Age ≥ 18 years
• Participation in a trial with investigational drugs within 30 days
• Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
• Consumption of alcoholic beverages \>15 drinks/week
• Tobacco smoking \>10 cigarettes/day
• Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)

Sponsors & Collaborators

• University Hospital, Basel, Switzerland: lead

Study Sites (1)

University Hospital Basel

Basel, 4031, Switzerland

RECRUITING

MeSH Terms

Conditions

Diabetes Insipidus, Neurogenic; Diabetes Insipidus

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Study Officials

• Mirjam Christ-Crain, Prof.

  University Hospital, Basel, Switzerland

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mirjam Christ-Crain, Prof.

CONTACT

+41 61 265 25 25; Mirjam.Christ-Crain@usb.ch

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Part 1 is a double-blinded, randomized and cross-over proof-ofconcept trial Part 2 is an open-labeled single arm pilot study

Study Record Dates

• First Submitted: November 28, 2025
• First Posted: December 10, 2025
• Study Start: January 9, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: February 13, 2026

Record last verified: 2026-02

Locations

CH (1)